Cargando…

Four‐factor prothrombin complex concentrate reverses apixaban‐associated bleeding in a rabbit model of acute hemorrhage

BACKGROUND: Apixaban is a direct factor Xa inhibitor approved for the treatment and prevention of thromboembolic disease. There is a lack of data regarding its reversal in cases of acute bleeding or prior to emergency surgery that needs addressing. OBJECTIVES: This study assessed whether a four‐fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herzog, E., Kaspereit, F., Krege, W., Mueller‐Cohrs, J., Doerr, B., Niebl, P., Dickneite, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	COAGULATION
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738416/ https://www.ncbi.nlm.nih.gov/pubmed/26447393 http://dx.doi.org/10.1111/jth.13165

Ejemplares similares

Four-factor prothrombin complex concentrate (Beriplex® P/N) mediated reversal of apixaban-induced bleeding in a rabbit model
por: Herzog, E, et al.
Publicado: (2015)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Reversal of edoxaban-induced anticoagulation by the four-factor prothrombin complex concentrate Beriplex(® )in a rabbit model
por: Herzog, E, et al.
Publicado: (2014)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

Acquired bleeding model induced by dilutional coagulopathy in the rabbit
por: Pragst, I, et al.
Publicado: (2009)

Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models
por: Ghosh, Subhajit, et al.
Publicado: (2021)

Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model
por: Kaspereit, F., et al.
Publicado: (2010)

Novel, high incidence exercise-induced muscle bleeding model in hemophilia B mice: rationale, development and prophylactic intervention
por: Tranholm, M, et al.
Publicado: (2015)

Towards patient‐specific management of trauma hemorrhage: the effect of resuscitation therapy on parameters of thromboelastometry
por: Juffermans, Nicole P., et al.
Publicado: (2019)

Treatment of the coagulation deficit during extracorporeal circulation in a porcine model by a prothrombin complex concentrate
por: Kaspereit, F, et al.
Publicado: (2010)

A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X
por: TAI, S J, et al.
Publicado: (2008)

Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers
por: Nagalla, S, et al.
Publicado: (2016)

The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model
por: SU, E J, et al.
Publicado: (2011)

Redox control of β(2)-glycoprotein I–von Willebrand factor interaction by thioredoxin-1
por: PASSAM, F H, et al.
Publicado: (2010)

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein
por: PETERS, R T, et al.
Publicado: (2013)

Coagulation factor XII protease domain crystal structure
por: Pathak, M, et al.
Publicado: (2015)

Plasma free fatty acid levels influence Zn(2+)-dependent histidine-rich glycoprotein–heparin interactions via an allosteric switch on serum albumin
por: Kassaar, O, et al.
Publicado: (2015)

An engineered U1 small nuclear RNA rescues splicing-defective coagulation F7 gene expression in mice
por: Balestra, D, et al.
Publicado: (2014)

A simple flow cytometry method improves the detection of phosphatidylserine-exposing extracellular vesicles
por: Arraud, N, et al.
Publicado: (2015)

Dexamethasone inhibits endotoxin‐induced coagulopathy in human lungs
por: Bartko, J., et al.
Publicado: (2016)

Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A
por: Nguyen, G. N., et al.
Publicado: (2016)

Conformational quiescence of ADAMTS‐13 prevents proteolytic promiscuity
por: South, K., et al.
Publicado: (2016)

Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation
por: Hamad, B. K., et al.
Publicado: (2017)

Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation
por: Healey, J. F., et al.
Publicado: (2018)

The role of β‐barrels 1 and 2 in the enzymatic activity of factor XIII A‐subunit
por: Hethershaw, E. L., et al.
Publicado: (2018)

Genomeâwide analysis of genetic determinants of circulating factorÂVIIâactivating protease (FSAP) activity
por: Olsson, M., et al.
Publicado: (2018)

Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non‐recurrent disease
por: Baker, Stephen R., et al.
Publicado: (2019)

Androgen receptor dampens tissue factor expression via nuclear factor‐κB and early growth response protein 1
por: Hoesel, B., et al.
Publicado: (2018)

Myeloid but not epithelial tissue factor exerts protective anti‐inflammatory effects in acid aspiration‐induced acute lung injury
por: Kral‐Pointner, J. B., et al.
Publicado: (2017)

Factor XII truncation accelerates activation in solution
por: de Maat, S., et al.
Publicado: (2018)

Crosslinked clots formed independently of factor XIII and without fibrinogen‐to‐fibrin conversion – is this a liver‐specific phenomenon?
por: Lisman, T.
Publicado: (2018)

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays
por: Horn, C., et al.
Publicado: (2018)

Sirtilins – the new old members of the vitamin K‐dependent coagulation factor family
por: Dahms, Sven O., et al.
Publicado: (2019)

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Correction to: Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Comparison of prothrombin complex concentrate and fresh frozen plasma on thrombin generation and hemorrhage in experimental dilutional coagulopathy
por: Dickneite, G, et al.
Publicado: (2008)

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
por: Costa, Olivia S., et al.
Publicado: (2022)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model
por: Dickneite, G., et al.
Publicado: (2009)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8f4bgmbtplc9i5s0ak6hsfnr60